Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Boston Scientific (NY:BSX)

95.12 -0.13 (-0.14%)
Official Closing Price Updated: 7:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Boston Scientific

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Medical device maker Boston Scientific Co. defies Medtech slowdown and delivers a solid Q1 2024 earnings report, and raises 2024 outlook. 
Via MarketBeat
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
(BSX) - Analyzing Boston Scientific's Short Interest
Via Benzinga
Key Takeaways From Boston Scientific Analyst Ratings
Via Benzinga
Unveiling 13 Analyst Insights On Boston Scientific
Via Benzinga
Top 4 Health Care Stocks That May Plunge This Month
Via Benzinga
Staar Surgical Stock Climbs The Leadership Ladder With Jump To 84 RS Rating
On Thursday, implantable lens maker Staar Surgical stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. 
Via Investor's Business Daily
Wabtec Rumbles onto Stock Spotlight List. Check These Lists For Best Stocks To Watch And Buy
Wabtec leads a diverse group climbing aboard the Stock Spotlight list, including defense and aerospace play TransDigm. 
Via Investor's Business Daily
Boston Scientific Lifts 2024 Profit Forecast On Strong Growth From Cardiovascular Devices, Stock Soars
Boston Scientific reports impressive Q1 earnings, with revenues of $3.86 billion, beating estimates. Cardiovascular segment leads with $2.4 billion sales, up 15.9%. Outlook: 2024 net sales growth... 
Via Benzinga
Hilton Worldwide Reports Upbeat Results, Joins Hasbro, Vertiv Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Looking Into Boston Scientific's Recent Short Interest
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $8,100 Today
Via Benzinga
Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
BSX Stock Earnings: Boston Scientific Beats EPS, Beats Revenue for Q1 2024
BSX stock results show that Boston Scientific beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Boston Scientific Pops Into Buy Zones On Solid First-Quarter Report
Boston Scientific heads for two different buy zones after topping Q1 views and hoisting guidance above expectations. 
Via Investor's Business Daily
NYSE:BSX may be ready to breakout.
Will BOSTON SCIENTIFIC CORP breakout? 
Via Chartmill
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,200 Today
Via Benzinga
Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What's Driving Markets Wednesday?
Rising Treasury yields have investors cautious despite positive news from the earnings season. The yield on the long-dated 30-year Treasury bond has surged to 4.79%. It’s on track to close at the... 
Via Benzinga
Topics Bonds
Exposures Debt Markets
Nasdaq Futures Get A Lift From Tesla, Texas Instruments Earnings: Analyst Points To Key Catalyst For Boosting Rally
Nasdaq and S&P 500 futures signaled a higher open on Wednesday, thanks to upbeat guidance from EV giant Tesla, Inc. (NASDAQ:TSLA) and semiconductor m 
Via Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
FDA Classifies Boston Scientific's Recall For Device To Stop Blood Flow As 'Most Serious'
Boston Scientific announces a Class I recall of Obsidio Embolic due to high-risk implications for lower GI bleeding embolization. Potential adverse effects include bowel ischemia, necessitating major... 
Via Benzinga
Exposures Product Safety
Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 10 Years
Via Benzinga
Medical Device Manufacture Integer To Gain From Expanding Pulsed Field Ablation Market, Earns Upgrade From BofA
BofA Securities' upgrades Integer, highlighting the growth potential of pulsed field ablation (PFA) in atrial fibrillation treatment. With projections of PFA sales skyrocketing from $100-200 million in... 
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
5 Things to Know in Investing This Week
The Shockwave Issue 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Johnson & Johnson Strong Strategic Fit For Shockwave Medical, But Medtronic, Boston Scientific Could Be Other Bidder, Says Analyst
Johnson & Johnson reportedly in talks to acquire Shockwave Medical. Potential acquisition aligns with J&J's interest in expanding into cardiovascular devices. Piper Sandler considers J&J a potential... 
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
A look at five stocks that are seeing increased attention from investors and Benzinga readers. The list includes several large cap stocks for the week. 
Via Benzinga
Why Abbott's Formula-Related Sell-Off Could Be A Buying Opportunity, Says Analyst
Fellow infant formula maker Reckitt Benckiser was ordered to pay $60 million to a mother whose baby died after eating Enfamil. 
Via Investor's Business Daily
Topics Death
Exposures Death
Tandem Diabetes Care Stock Belongs On Your Watchlist As RS Rating Jump Higher
On Monday, Tandem Diabetes Care stock received an upgrade to its Relative Strength (RS) Rating, from 68 to 78. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS